Document is current

Article History

Received: 20 September 2021

Accepted: 25 October 2021

First Online: 6 November 2021

Declarations

:

: Not applicable.

: Not applicable.

: AC: Advisory Board, Consultancy, Lectures: Berlin Chemie, Eli Lilly, Novo Nordisk, Mitsubishi, Roche Diagnostics, Theras.DC: Advisory Board, Lectures, Consultancy: Novo Nordisk, Eli Lilly, Sanofi, Servier, MSD, Merck, Alfa Wasserman, Bayer, Astra Zeneca, Boehringer-Ingelheim.CC: The authors declare that they have no competing interests.FC: research grants from Swedish Research Council, Swedish Heart & Lung Foundation, and King Gustav V and Queen Victoria Foundation, as well as advisory board, consultancy fees from Abbott, AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim Merck Sharp & Dohme, Lilly, Novo Nordisk, and Pfizer.ACD: The authors declare that they have no competing interests.BI: Advisory Board, Consultancy, Lectures: Novo Nordisk, Sanofi, Eli Lilly, Bayer, AstraZeneca, Boehringer Ingelheim, Pfizer, MSD, Roche.NML: Advisory Board and Lectures for NovoNordisk, Sanofi, Boehringer Ingelheim, Astra Zeneca, Medtronic, Roche, Eli Lilly, Berlin Chemie.FP: lectures for Berlin Chemie.OS: AstraZeneca, Bayer, Boehringer Ingelheim, Grünethal, Lilly, MSD, Mundipharma, Novo Nordisk, Roche, Sanofi, Wörwag.PMS: Lectures for Servier, Astra Zeneca, Respicardia, Menarini; Consultancy agreement for Boehringer Ingelhein, Vifor Pharma, Novartis, Roche diagnostic.PV: Lectures for Abbott, AstraZeneca, Bayer, Eli Lilly, Hikma Pharmaceuticals, Merck Sharp & Dohme, Novo Nordisk, Novartis, Pfizer, Sanofi; research grants from Abbott, Bristol-Myers-Squibb–AstraZeneca, Novo Nordisk; participation in expert committees for AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Daiichi Sankyo, Sanofi, Servier, Stendo.ES: Personal fees from Oxford Diabetes Trials Unit, Bayer, Berlin Chemie, Boehringer Ingelheim, Menarini, Merck Serono, EXCEMED, Novartis, Novo Nordisk, and Sanofi.